Latest News & Updates

Latest Articles
Sumanta Kumar Pal, MD, provides insight on the FDA approval of the TKI lenvatinib in combination with everolimus, an mTOR inhibitor as a treatment for patients with advanced RCC following prior antiangiogenic therapy.
PUBLISHED: May 25, 2016
The majority of patients with pancreatic adenocarcinoma are diagnosed with late-stage, unresectable tumors, a setting in which combination chemotherapy remains the mainstay.
PUBLISHED: May 25, 2016
Robert Ferris, MD, PhD, explains the potential of nivolumab, its future, and its limitations in the treatment of patients with head and neck cancer.
PUBLISHED: May 24, 2016
Using the Decipher Prostate Cancer Classifier assay to predict which patients might respond to hormonal therapy has resulted in the discovery and validation of an adjuvant androgen-deprivation therapy resistance signature.
PUBLISHED: May 24, 2016
The RAS family of genes, implicated in more than 30% of human cancers, has proved to be such a difficult molecular driver to target that researchers have considered it "undruggable." A 3-year-old effort by the National Cancer Institute aims to change that—and is making headway.
PUBLISHED: May 24, 2016
Latest Peer Exchange Discussions
Panelists Mark A. Socinski, MD; Gregory J. Riely, MD, PhD; Jared Weiss, MD; Thomas E. Stinchcombe, MD; and Benjamin P. Levy, MD; provide insight on the treatment options in ALK-positive lung cancer. View Now
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections: 11th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®May 29, 20161.5
32nd Annual Miami Breast Cancer Conference® Community Practice ConnectionsMay 29, 20161.25
Community Practice Connections: 8th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary MalignanciesMay 30, 20161.5
2nd Annual Miami Lung Cancer Conference™ Medical Crossfire® Case DiscussionMay 31, 20163.75